Home › Funds › Redmile Group, LLC › NGNE
Redmile Group, LLC position in NGNE
NEUROGENE INC COM · Health Care
Redmile Group, LLC reported holding 1,412,199 shares of NGNE (NEUROGENE INC COM) in its Q2 2026 13F filing — a position valued at US$44.4M, representing 2.98% of its reported portfolio and ranking #10 among its reported holdings. Redmile Group, LLC has disclosed NGNE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Redmile Group, LLC's NGNE position evolved
Redmile Group, LLC first disclosed a stake in NGNE in Q4 2023 at 946,897 shares (US$18.4M). The position peaked in Q1 2024 at 935,252 shares, worth US$47.6M. Across 11 filings, Redmile Group, LLC increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,412,199 shares valued at US$44.4M — a reduction of -47,400 shares quarter over quarter.. Notable position changes include a 37% increase in Q4 2024 (shares fell 49% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 946.90K | $18.35M | New |
| Q1 2024 | 935.25K | $47.60M | Reduce |
| Q2 2024 | 1.01M | $36.89M | Add |
| Q3 2024 | 964.35K | $40.46M | Reduce |
| Q4 2024 | 1.32M | $30.17M | Add |
| Q1 2025 | 1.31M | $15.32M | Reduce |
| Q2 2025 | 1.28M | $19.09M | Reduce |
| Q3 2025 | 1.30M | $22.51M | Add |
| Q4 2025 | 1.46M | $30.07M | Add |
| Q1 2026 | 1.46M | $29.43M | Hold |
| Q2 2026 | 1.41M | $44.41M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NGNE and 13F data
NGNE (NEUROGENE INC COM) is a Health Care company. 37 other funds we track also report a position in NGNE — the largest reported positions include Samsara BioCapital, LLC (US$54.0M), Casdin Capital (US$48.6M), RTW INVESTMENTS, LP (US$42.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NGNE
- Samsara BioCapital, LLC 1.72M sh · $54.00M · Q2 2026
- Casdin Capital 1.55M sh · $48.60M · Q2 2026
- RTW INVESTMENTS, LP 1.36M sh · $42.85M · Q2 2026
- EcoR1 Capital, LLC 1.27M sh · $39.98M · Q2 2026
- BAKER BROS. ADVISORS LP 991.69K sh · $31.19M · Q2 2026
- Trails Edge Capital Partners, LP 714.88K sh · $22.48M · Q2 2026
- GREAT POINT PARTNERS LLC 352.18K sh · $11.08M · Q2 2026
- DAFNA Capital Management LLC 89.03K sh · $2.80M · Q2 2026
More on Redmile Group, LLC
FAQ
How long has Redmile Group, LLC held NGNE?
Redmile Group, LLC has disclosed NGNE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is Redmile Group, LLC's current position in NGNE?
As of Q2 2026, Redmile Group, LLC holds 1.41M shares of NGNE (NEUROGENE INC COM), valued at $44.41M, representing 2.98% of its reported portfolio and ranking #10.
Has Redmile Group, LLC been buying or selling NGNE?
In the latest 13F filing (Q2 2026), Redmile Group, LLC reduced its position in NGNE. The position peaked in Q1 2024 at 935.25K shares.
Which other funds hold NGNE?
Other major institutional holders of NGNE include Samsara BioCapital, LLC, Casdin Capital, RTW INVESTMENTS, LP, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.